Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic
May 11, 2022 06:00 ET
|
Immuron Limited
Key Points US Naval Medical Research Centre (NMRC) submits IND application to the U.S. Food and Drug administration (FDA)Two human phase II clinical trials to be conducted. One trial will focus on...
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™
May 09, 2022 06:00 ET
|
Immuron Limited
UPDATE Key Points Manufacture Completed of investigational medical products to be clinically evaluated by the Uniformed Services University (USU). The clinical program aims to determine the...
Immuron appoints Mr. Steven Lydeamore as Chief Executive Officer
May 05, 2022 20:22 ET
|
Immuron Limited
MELBOURNE, Australia, May 05, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Travelan® Global sales up 216%
April 27, 2022 06:00 ET
|
Immuron Limited
Key Highlights: North American Travelan® sales up by 185% YoY in Q3 FY22Global sales up 216% YoY in Q3 FY22.YTD March 31, FY22 worldwide Travelan® sales reached AU $392K, increasing 340% YoY. ...
Immuron new MTEC project proposal “Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease”
April 19, 2022 07:33 ET
|
Immuron Limited
Key Highlights: Immuron’s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award’Travelan Investigational New Drug (IND)...
Appointment of Paul Brennan as Non-Executive Director
March 16, 2022 09:30 ET
|
Immuron Limited
MELBOURNE, Australia, March 16, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Receives AUD $306,154 R&D Tax Concession Refund
January 17, 2022 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Receives European Patent on Drug Composition to Treat Travelers’ Diarrhea
January 13, 2022 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan
January 12, 2022 06:00 ET
|
Immuron Limited
Key Highlights: Immuron Awarded AU $4.8 (USD $3.43) million funding by the U.S. Department of Defense for TravelanU.S Naval Medical Research Center Received AU $1.4 (USD $1.02) million funding to...
US DoD Uniformed Services University Travelers’ Diarrhea Clinical Update
November 15, 2021 06:00 ET
|
Immuron Limited
Key Points Manufacture of investigational medical products to support the Uniformed Services University (USU) clinical program to evaluate the efficacy of Travelan® and two other non-antibiotic OTC...